Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Corline Biomedical AB OCF Yield % Related Terms
Corline Biomedical AB OCF Yield % Historical Data
* Premium members only.
The historical data trend for Corline Biomedical AB's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IZ7 vs VRTX, REGN, ALNY: OCF Yield % Comparison
For the Biotechnology subindustry, Corline Biomedical AB's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corline Biomedical AB OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corline Biomedical AB's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Corline Biomedical AB's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corline Biomedical AB (FRA:IZ7) has a OCF Yield % of -3.84 as of Jul. 14, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Corline Biomedical AB and its competitors. According to the industry distribution chart, Corline Biomedical AB ranks #532 out of 1410 companies in the Biotechnology industry, placing it in the top 37.7%.
Is Corline Biomedical AB's OCF Yield % too high?
Corline Biomedical AB's current OCF Yield % is -3.84. Based on the distribution chart, Corline Biomedical AB ranks #532 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Corline Biomedical AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Corline Biomedical AB's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Corline Biomedical AB ranks #532 out of 1410 companies for OCF Yield %. This puts Corline Biomedical AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Corline Biomedical AB and its competitors. Corline Biomedical AB's current OCF Yield % is -3.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corline Biomedical AB stock overvalued right now?
Corline Biomedical AB (FRA:IZ7) has a current OCF Yield % of -3.84. The stock's GF Value™ is €0.45, compared to a current price of €1.55 — trading 243.3% above its estimated fair value. The current OCF Yield % is -3.84. Corline Biomedical AB's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Corline Biomedical AB (FRA:IZ7), the current OCF Yield % is -3.84 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corline Biomedical AB (FRA:IZ7) Overvalued in 2026?
Based on GuruFocus' analysis, Corline Biomedical AB stock appears to be overvalued.
The current stock price of €1.55 is trading 243.3% above its estimated GF Value™ of €0.45.
Key valuation signals for FRA:IZ7:
OCF Yield %: -3.84
GF Value™: €0.45 vs. price of €1.55 (243.3% above fair value)
No single metric tells the full story. See the FRA:IZ7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body.
43GF Score
Get the complete analysis for FRA:IZ7
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IZ7 has been successfully added to your 
